JMJD1C and acute myeloid leukemia: Although a recent CRISPR/Cas9 screen showed that JMJD1C’s enzymatic activity domain (JmjC domain) is critical for MLLr leukemogenesis (Izaguirre-Carbonell et al., 2019), whether the JmjC domain is universally required for all types of AML that depend on the full-length protein for survival is still unknown.